

## Biophytis - Convening of another combined General Meeting at a Later Date

**Paris (France), Cambridge (Massachusetts, USA)**, May 11, 2020, 7:30 p.m. CEST – BIOPHYTIS (Euronext Growth Paris: ALBPS) a clinical-stage biotechnology company specialized in the development of drug candidates for treatment of aged related diseases, amongst which neuromuscular diseases, informs its shareholders that the combined General Meeting held on May 11, 2020 was unable to deliberate, as the required quorum was not reached.

Biophytis' combined General Meeting took place today behind closed doors, due to the COVID-19 pandemic. The shareholders taking part in the vote owned collectively 6 649 625 shares, or 16.74 % of the share capital, and 19.92 % of the voting rights.

The 20% quorum necessary for holding an ordinary general meeting on first call and the 25% quorum necessary for holding an extraordinary general meeting on first call have not been reached. Therefore, in the absence of the quorum required to rule on the ordinary and extraordinary resolutions, none of the proposed resolutions as listed in the meeting notice published in the *Bulletin des Annonces Légales Obligatoires* n ° 42 of April 6, 2020, has been put to the vote of the shareholders and the general meeting is adjourned.

Shareholders will therefore be invited to another combined General Meeting, on the second call, to be held at a later date with the same agenda.

All of the documents regarding this combined General Meeting are available to shareholders on the Company's website: [www.biophytis.com](http://www.biophytis.com), in the section Investors / General Assembly 2020: <https://www.biophytis.com/en/action/assemblee-generale-2020/>.

If you are a Biophytis shareholder and wish to vote on the resolutions, you can:

- vote via your bank's web portal, if your bank subscribes to the VOTACCESS platform, **this method is strongly recommended in the current context of Covid-19,**
- vote by post or proxy, in accordance with the T&Cs indicated in the Shareholders' letter and in the *Bulletin des Annonces Légales Obligatoires* n ° 42 of April 6, 2020 available on Biophytis' website

The vote of shareholders who submitted their vote via the post, email or the Internet for the first general meeting remains valid and counted for the general meeting on the second call.

Shareholders who did not vote by post or proxy as part of the first combined General Meeting will be invited to send their forms and shareholder certificates after publication of the new meeting notice. By post : CACEIS Corporate Trust, Service Assemblées Générales Centralisées - 14, rue Rouget de L'Isle - 92862 ISSY-LES-MOULINEAUX Cedex 9, or via email: [ct-assemblees@caceis.com](mailto:ct-assemblees@caceis.com)

\*\*\*\*

## About BIOPHYTIS

Biophytis SA is a clinical-stage biotechnology company specialized in the development of drug candidates to slow down degenerative processes and improve functional abilities in patients with age-related diseases, especially neuromuscular diseases.

Sarconeos (BIO101), our leading drug candidate, is a small molecule, administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in the United States and Europe. A pediatric formulation of BIO101 is being developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company plans to start the clinical development in H2 2020.

Sarconeos (BIO101) will also be developed as a treatment for Covid-19 (Coronavirus) for which the company has filed a clinical trial application with the French Regulatory Authority (ANSM).

The company is based in Paris, France, and Cambridge, Massachusetts. The company's common shares are listed on the Euronext Growth Paris market (Ticker: ALBPS -ISIN: FR0012816825).

For more information [www.biophytis.com](http://www.biophytis.com).

### **Biophytis Contact for Investor Relations**

Evelyne Nguyen, CFO

[evelyne.nguyen@biophytis.com](mailto:evelyne.nguyen@biophytis.com)

### **Media contact**

***Citigate Dewe Rogerson***

Sylvie Berrebi/ Nathaniel Dahan/ David Dible / Quentin Dussart

[biophytis@citigatedewerogerson.com](mailto:biophytis@citigatedewerogerson.com)

Tel: +44 (0) 20 7638 9571 / +33 (0)6 59 42 29 35